Related Experiment Video
Updated: Jun 6, 2025
Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
Circulating tumor cells in breast cancer: clinical validity and utility
Thibault Thomas-Bonafos1,2, Jean Yves Pierga1,2,3, François-Clément Bidard1,2,4
1Institut Curie, Department of Medical Oncology, Paris, France.
Abstract:
Circulating tumor cells (CTCs) have been extensively studied in breast cancer (BC), with large studies establishing CTCs as a robust prognostic biomarker in early and metastatic breast cancer (MBC). Several phase II and phase III trials have investigated the clinical utility of CTCs in BC. Here, we outline the current landscape for the use of CTCs in the clinic at different stages of BC, focusing first on early BC, then on MBC, with a particular focus on interventional clinical trials based on CTCs.
